Stryker (NYSE:SYK) Announces Earnings Results, Misses Estimates By $0.38 EPS

Stryker (NYSE:SYK) posted its earnings results on Thursday. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38), FiscalAI reports. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The firm had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. During the same quarter in the previous year, the business posted $2.84 earnings per share. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. Stryker updated its FY 2026 guidance to 14.900-15.100 EPS.

Here are the key takeaways from Stryker’s conference call:

• The company experienced a late‑Q1 cyber incident that caused a global operational disruption, delayed shipments and revenue recognition, and reduced manufacturing absorption; Stryker says systems were restored and manufacturing was fully operational by the week of April 1, with results expected to normalize over the year.
• Stryker reiterated full‑year guidance despite the disruption, forecasting organic net sales growth of 8%–9.5% and adjusted EPS of $14.90–$15.10, expecting most lost Q1 sales to be recovered throughout the rest of 2026.
• Q1 headline metrics were muted—organic sales growth of 2.4% (U.S. 1.9%, international 3.9%), adjusted EPS of $2.60 (down 8.5% vs. 2025), adjusted gross margin 63.6% (‑190 bps) and adjusted operating margin 21.1% (‑180 bps), with tariffs, higher interest expense and the cyber event cited as drivers.
• M&A remains active—Stryker announced the agreement to acquire Amplitude Vascular Systems (expected to close in Q2) to expand peripheral vascular and broader cardiovascular offerings and said it has capacity to pursue additional acquisitions (gross debt/EBITDA ~2.1x).
• Organizational and product momentum in orthopedics—Stryker launched the consolidated Ortho Tech segment (Mako + Enabling Tech + instruments), reported a record Q1 for Mako installations, plans a Mako Shoulder full launch on Mako 4 midyear, and cited strong early feedback for new robotic and instrument products.

Stryker Price Performance

Shares of SYK traded down $19.70 during mid-day trading on Friday, reaching $295.43. The company had a trading volume of 4,516,333 shares, compared to its average volume of 2,089,217. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89. Stryker has a 1-year low of $294.55 and a 1-year high of $404.87. The company has a market capitalization of $113.15 billion, a price-to-earnings ratio of 35.17, a P/E/G ratio of 1.84 and a beta of 0.92. The company’s 50 day simple moving average is $345.67 and its 200 day simple moving average is $356.95.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st were paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date was Tuesday, March 31st. Stryker’s dividend payout ratio (DPR) is presently 41.90%.

Analyst Upgrades and Downgrades

Several analysts have issued reports on SYK shares. Barclays restated an “overweight” rating and issued a $469.00 price target on shares of Stryker in a research report on Monday, February 2nd. The Goldman Sachs Group cut their price target on shares of Stryker from $403.00 to $357.00 and set a “neutral” rating for the company in a report on Thursday, April 9th. Truist Financial lowered their price objective on shares of Stryker from $395.00 to $380.00 and set a “hold” rating for the company in a research report on Wednesday, April 15th. Deutsche Bank Aktiengesellschaft set a $315.00 price objective on shares of Stryker in a research report on Friday. Finally, Piper Sandler reiterated an “overweight” rating on shares of Stryker in a research report on Tuesday, January 27th. Sixteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, Stryker has a consensus rating of “Moderate Buy” and a consensus target price of $403.90.

Key Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker reaffirmed its FY‑2026 outlook (organic sales growth 8%–9.5% and adjusted EPS $14.90–$15.10), which reduces downside risk from the Q1 miss and signals management confidence in recovery. Seeking Alpha: Stryker maintains 2026 outlook
• Positive Sentiment: Despite the headline miss, Stryker reported higher net income and a large jump in operating cash flow, showing underlying cash generation and balance‑sheet resilience. Quiver Quantitative: Q1 results summary
• Neutral Sentiment: Several sell‑side firms reduced price targets (JPMorgan, Wells Fargo, Needham, BTIG) but generally kept “buy/overweight” ratings — signaling lowered near‑term expectations while maintaining longer‑term conviction. Benzinga: analyst updates
• Neutral Sentiment: Stryker will present at the Bank of America Global Healthcare Conference on May 13 — a chance for management to address the cyber incident, recovery timeline and capital allocation. GlobeNewswire: conference participation
• Negative Sentiment: Q1 adjusted EPS and revenue missed Street estimates (adjusted EPS missed consensus; revenue ~$6.02B vs. ~6.34B expected), weighed down by softer demand in some implant categories and the operational impact of a cyberattack. Zacks: Q1 earnings & cyber disruption
• Negative Sentiment: Management said a cyber incident disrupted production and dented margins and growth in the quarter; that operational uncertainty is driving investor caution until full recovery is visible. Reuters: cyber incident and muted demand

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 250,000 shares of the stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total value of $90,730,000.00. Following the completion of the sale, the director owned 2,457,331 shares of the company’s stock, valued at approximately $891,814,566.52. This represents a 9.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Atlas Capital Advisors Inc. bought a new position in shares of Stryker in the 4th quarter worth about $27,000. United Financial Planning Group LLC bought a new stake in shares of Stryker in the 3rd quarter valued at $27,000. Strive Asset Management LLC acquired a new position in shares of Stryker during the 3rd quarter valued at $30,000. Birchwood Financial Partners Inc. acquired a new position in shares of Stryker during the 4th quarter valued at $35,000. Finally, Kemnay Advisory Services Inc. bought a new position in Stryker during the fourth quarter worth $49,000. 77.09% of the stock is owned by institutional investors.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.